Microcap Ledger Puma Biotechnology, Inc. $PBYI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Los Angeles, CA
- Fiscal year end
- December 31
- Shares outstanding
- 51,620,066 [10-Q 2026-08-06]
What the company doesAI summary of filing
Puma Biotechnology is a biopharmaceutical company that commercializes and develops cancer treatments. The company's primary revenue-generating product is NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved for treating HER2-positive breast cancer in both early-stage and metastatic settings. NERLYNX is marketed in the United States through a direct specialty sales force and in over 40 countries outside the U.S. through licensing agreements. The company also develops alisertib, an Aurora Kinase A inhibitor in-licensed from Takeda, which is in clinical development for small cell lung cancer and hormone receptor-positive breast cancer. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $101.32M | $4.44M | $17.04M | $36.54M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $228.37M | $31.11M | $41.80M | $29.64M | [10-K 2026-02-26] |
| FY ended Dec 2024 | $230.47M | $30.28M | $38.92M | $69.22M | [10-K 2026-02-26] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 49,087,684 | [10-Q 2024-11-07] |
| 2025-02-24 | 49,610,799 | [10-K 2025-02-27] |
| 2025-05-05 | 49,638,093 | [10-Q 2025-05-08] |
| 2025-08-04 | 50,370,723 | [10-Q 2025-08-07] |
| 2025-11-03 | 50,391,107 | [10-Q 2025-11-06] |
| 2026-02-23 | 50,876,487 | [10-K 2026-02-26] |
| 2026-05-04 | 50,899,456 | [10-Q 2026-05-07] |
| 2026-08-03 | 51,620,066 | [10-Q 2026-08-06] |
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-14 | Wilson Troy Edward | sell | 5,000 | $9.10 | [4 2026-09-16] |
| 2026-09-14 | Cesano Alessandra | exercise | 50,000 | $2.93 | [4 2026-09-16] |
| 2026-09-14 | Cesano Alessandra | sell | 62,150 | $9.12 | [4 2026-09-16] |
| 2026-07-06 | Auerbach Alan H | sell | 44,058 | $8.26 | [4 2026-07-08] |
| 2026-07-06 | Hunt Douglas M | sell | 8,460 | $8.26 | [4 2026-07-08] |
| 2026-07-06 | Nougues Maximo F | sell | 9,386 | $8.26 | [4 2026-07-08] |
| 2026-06-12 | Wilson Troy Edward | sell | 10,800 | $7.20 | [4 2026-06-15] |
| 2026-06-12 | Stuglik Brian M | sell | 8,100 | $7.20 | [4 2026-06-15] |
| 2026-06-12 | Senderowicz Adrian | sell | 27,000 | $7.20 | [4 2026-06-15] |
| 2026-06-11 | Wilson Troy Edward | grant | 27,000 | — | [4 2026-06-15] |
| 2026-06-11 | Stuglik Brian M | grant | 27,000 | — | [4 2026-06-15] |
| 2026-06-11 | Senderowicz Adrian | grant | 27,000 | — | [4 2026-06-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-06-16 | 8-K | Shareholder vote results |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations |
| 2026-04-28 | DEF 14A | Proxy statement |
| 2026-04-07 | PRE 14A | Proxy statement |
| 2026-03-27 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-02-26 | 10-K | Annual report |
| 2026-02-26 | 8-K | Results of operations |
| 2025-11-06 | 10-Q | Quarterly report |
Alerts for $PBYI
Email me when Puma Biotechnology, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.